NCT04157985View on ClinicalTrials.gov

Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors

PHASE3RecruitingINTERVENTIONAL
Enrollment

578

Participants

Timeline

Start Date

November 15, 2019

Primary Completion Date

November 30, 2030

Study Completion Date

November 30, 2031

Conditions
Advanced Solid TumorsNSCLCBladder CancerHNSCCRenal CancerMelanomaAnal CancerColorectal CancerCholangiocarcinomaGastric CancerHepatocellular CarcinomaMerkel Cell CarcinomaCervical Cancer
Interventions
DRUG

Continue PD-1/PD-L1 Inhibitors treatment

Continued treatment with PD-1/PD-L1-1 inhibitor

OTHER

Discontinue PD-1/PD-L1-1 inhibitor

Discontinued treatment with PD-1/PD-L1-1 inhibitor

Trial Locations (1)

15232

RECRUITING

UPMC Hillman Cancer Center, Pittsburgh

All Listed Sponsors
lead

Dan Zandberg

OTHER

NCT04157985 - Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors | Biotech Hunter | Biotech Hunter